Latest Breaking News On - நிறுவனம் கியூரி - Page 11 : comparemela.com

PEP-Therapy raises €2 75 million in Series A financing to advance its lead candidate, PEP-010, into the clinic

PEP-Therapy raises €2 75 million in Series A financing to advance its lead candidate, PEP-010, into the clinic
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalMichele marzolaBernard majoieUrogen pharmaSylvie berrebiPhilippe tramoyLaboratoires fournierAntoine prestatGustave roussyNathaniel dahanInstitut curieCitigate dewe rogersonSeed fundFrench national agency for medicinesMilan stock exchange

Harmonic Pharma: molecules in a single click

Originally used in medicine, Harmonic Pharma’s digital solutions are also of interest to actors in the fields of chemistry, agri-food, cosmetics and defence. Located in Nancy on the Artem campus, the start-up’s development is based on its flagship tool: a platform for characterising and predicting the safety of chemical compounds from different sources.

Gustave roussyInstitut curieInria nancyMichel souchetArnaud sinan karabogaDefence innovation agencyArnaud sinanSinan karabogaChemical rangeDirectorate generalநிறுவனம் கியூரிஇயக்குநரகம் ஜநரல்

Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update

Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update > Several major clinical milestones achieved in 2020 by AsiDNA, including promising initial results in combination with chemotherapy and the launch of a new study to evaluate the abrogation of resistance to a targeted therapy > Cash position of €14.5 million at December 31, 2020 supplemented by €14.7 million in new financing obtained in early 2021 > Extended financial visibility through the end of 2022, enabling the expansion of clinical and industrial development of AsiDNA Regulatory News: https://us02web.zoom.us/webinar/register/WN T6v8Hc8TRU67rKXPrz2nXw Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO) (Paris:ALONX) (NASDAQ OMX:ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today reported its consolidated financial results for the fiscal ending December 31,

United statesFrance generalJean pierre kinetNicolas merigeauJulien miaraAcrotech biopharmaVectans pharmaJudith grecietEmmanuel huynhOnxeo sa euronextValerie leroyGustave roussyInstitut curieEuropean named patient programCurie instituteTrademark office

OncoDNA and Institut Curie test the clinical utility of personalized liquid biopsy in head and neck cancers

Search jobs 15-Apr-2021 OncoDNA and Institut Curie test the clinical utility of personalized liquid biopsy in head and neck cancers THE ONCOFOLLOW™ TESTS WILL HELP MONITOR DISEASE PROGRESSION IN PATIENTS UNDER TREATMENT WITHIN THE SCANDARE STUDY OncoDNA, a theranostic and genomic company specializing in precision medicine, announced the launch of a research project in collaboration with the French foundation for cancer research Institut Curie. The objective of this project is to assess the clinical utility of liquid biopsy for head and neck cancer patient monitoring. Initiated in 2016 by Institut Curie, the SCANDARE study aims to incorporate new dimensions to precision medicine. SCANDARE consists of integrating microenvironment and immune parameters into the analysis of a tumor along with the molecular alterations of the tumor. As part of the study, Institut Curie has teamed up with OncoDNA to evaluate the utility of liquid biopsy

France generalMarie curieChristophe le tourneauInstitut curieHead of department drug developmentScientific directorProfessor christophe le tourneauDrug developmentCarnot curieபிரான்ஸ் ஜநரல்மேரி கியூரிகிறிஸ்டோஃப் லெ தொர்னேஔநிறுவனம் கியூரிஅறிவியல் இயக்குனர்ப்ரொஃபெஸர் கிறிஸ்டோஃப் லெ தொர்னேஔமருந்து வளர்ச்சி

Onxeo S A : Onxeo Announces the Success of Its Rights Issue With €9 7 Million Raised

This transaction will accelerate the development of the Company and its portfolio and extend its financial horizon to the end of 2022, beyond major clinical milestones expected in the next 18 months Regulatory

United statesFrance generalMartial valinNicolas merigeauJudith grecietEmmanuel huynhValerie leroyOnxeo sa euronextGustave roussyInstitut curieNordea bank abpEuronext growth parisNasdaq first north growth copenhagueNew sharesGeneral meetingNasdaq first north growth copenhagen